Is Teva Pharma Stock a Good Investment?
Teva Pharma Investment Advice | TEVA |
- Examine Teva Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Teva Pharma's leadership team and their track record. Good management can help Teva Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Teva Pharma's business and its evolving consumer preferences.
- Compare Teva Pharma's performance and market position to its competitors. Analyze how Teva Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Teva Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Teva Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Teva Pharma Industries stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Teva Pharma Industries is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Teva Pharma Stock
Researching Teva Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 53.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Teva Pharma Industries has Price/Earnings To Growth (PEG) ratio of 1.84. The entity recorded a loss per share of 0.5. The firm last dividend was issued on the 27th of November 2017. Teva Pharma had 2:1 split on the 1st of July 2004.
To determine if Teva Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Teva Pharma's research are outlined below:
| The company currently holds 20.15 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Teva Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharma Industries sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 15.85 B. Net Loss for the year was (615 M) with profit before overhead, payroll, taxes, and interest of 6.97 B. | |
| Teva Pharma has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: Multiple Sclerosis Market To Reach USD .9 Billion By 2032, Report By DataHorizzon Research |
Teva Pharma Quarterly Good Will |
|
Teva Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Teva Pharma Industries. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Teva Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Teva Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Teva Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2001-04-24 | 2001-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2000-05-04 | 2000-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
1998-05-11 | 1998-03-31 | 0.06 | 0.05 | -0.01 | 16 | ||
1998-02-24 | 1997-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
1996-11-11 | 1996-09-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2002-04-29 | 2002-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2002-02-14 | 2001-12-31 | 0.15 | 0.17 | 0.02 | 13 | ||
1996-08-15 | 1996-06-30 | 0.05 | 0.03 | -0.02 | 40 |
Teva Pharma Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Teva target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Teva Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 13 | Buy |
Most Teva analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Teva stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Teva Pharma Industries, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTeva Pharma Target Price Projection
Teva Pharma's current and average target prices are 13.81 and 10.56, respectively. The current price of Teva Pharma is the price at which Teva Pharma Industries is currently trading. On the other hand, Teva Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Teva Pharma Market Quote on 28th of April 2024
Target Price
Analyst Consensus On Teva Pharma Target Price
Teva Pharma Analyst Ratings
Teva Pharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Teva Pharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Teva Pharma's financials, market performance, and future outlook by experienced professionals. Teva Pharma's historical ratings below, therefore, can serve as a valuable tool for investors.Know Teva Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Teva Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Teva Pharma Industries backward and forwards among themselves. Teva Pharma's institutional investor refers to the entity that pools money to purchase Teva Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2023-12-31 | 15.1 M | Capital Research & Mgmt Co - Division 3 | 2023-12-31 | 10 M | Australiansuper Pty Ltd | 2023-12-31 | 9 M | Sound Shore Management Inc | 2023-12-31 | 8.9 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 8.2 M | Geode Capital Management, Llc | 2023-12-31 | 7.8 M | Goldman Sachs Group Inc | 2023-12-31 | 7.6 M | Alyeska Investment Group, L.p. | 2023-09-30 | 6.5 M | Eversept Partners, Llc | 2023-12-31 | 6.2 M | Blackrock Inc | 2023-12-31 | 41.7 M | Ion Asset Management Ltd. | 2023-12-31 | 40.3 M |
Teva Pharma's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 15.64 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Teva Pharma's market, we take the total number of its shares issued and multiply it by Teva Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Teva Pharma's profitablity analysis
Teva Pharma's profitability indicators refer to fundamental financial ratios that showcase Teva Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Teva Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Teva Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Teva Pharma's profitability requires more research than a typical breakdown of Teva Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | 0.01 | 0.01 | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.07) | (0.07) |
Determining Teva Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Teva Pharma is a good buy. For example, gross profit margin measures Teva Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Teva Pharma's profitability and make more informed investment decisions.
The data published in Teva Pharma's official financial statements usually reflect Teva Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Teva Pharma Industries. For example, before you start analyzing numbers published by Teva accountants, it's critical to develop an understanding of what Teva Pharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Teva Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Teva Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Teva Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Teva Pharma Industries. Please utilize our Beneish M Score to check the likelihood of Teva Pharma's management manipulating its earnings.
Evaluate Teva Pharma's management efficiency
Teva Pharma Industries has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0736) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 914.4 M, whereas Total Assets are forecasted to decline to about 26.4 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.71 | 8.30 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (12.90) | (12.26) | |
| Enterprise Value Over EBITDA | 6.70 | 6.37 | |
| Price Book Value Ratio | 1.56 | 1.48 | |
| Enterprise Value Multiple | 6.70 | 6.37 | |
| Price Fair Value | 1.56 | 1.48 | |
| Enterprise Value | 38.6 B | 40.5 B |
The analysis of Teva Pharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Teva Pharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Teva Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.062 |
Basic technical analysis of Teva Stock
As of the 28th of April, Teva Pharma has the Semi Deviation of 1.18, risk adjusted performance of 0.0885, and Coefficient Of Variation of 760.4. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Teva Pharma Industries, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Teva Pharma Industries, which can be compared to its competition. Please validate Teva Pharma Industries information ratio, and the relationship between the downside deviation and value at risk to decide if Teva Pharma is priced more or less accurately, providing market reflects its prevalent price of 13.81 per share. Given that Teva Pharma Industries has jensen alpha of 0.1543, we advise you to double-check Teva Pharma Industries's current market performance to make sure the company can sustain itself at a future point.Teva Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teva Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teva Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Teva Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark Sabag over three weeks ago Disposition of 100000 shares by Mark Sabag of Teva Pharma at 13.5209 subject to Rule 16b-3 | ||
Janet Vergis over six months ago Exercise or conversion by Janet Vergis of 15810 shares of Teva Pharma subject to Rule 16b-3 | ||
David Stark over a year ago Exercise or conversion by David Stark of 18430 shares of Teva Pharma subject to Rule 16b-3 |
Understand Teva Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Teva Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0885 | |||
| Market Risk Adjusted Performance | 0.2698 | |||
| Mean Deviation | 1.28 | |||
| Semi Deviation | 1.18 | |||
| Downside Deviation | 1.44 | |||
| Coefficient Of Variation | 760.4 | |||
| Standard Deviation | 1.76 | |||
| Variance | 3.11 | |||
| Information Ratio | 0.0809 | |||
| Jensen Alpha | 0.1543 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0994 | |||
| Treynor Ratio | 0.2598 | |||
| Maximum Drawdown | 11.6 | |||
| Value At Risk | (1.98) | |||
| Potential Upside | 3.1 | |||
| Downside Variance | 2.06 | |||
| Semi Variance | 1.38 | |||
| Expected Short fall | (1.46) | |||
| Skewness | 1.09 | |||
| Kurtosis | 3.72 |
| Risk Adjusted Performance | 0.0885 | |||
| Market Risk Adjusted Performance | 0.2698 | |||
| Mean Deviation | 1.28 | |||
| Semi Deviation | 1.18 | |||
| Downside Deviation | 1.44 | |||
| Coefficient Of Variation | 760.4 | |||
| Standard Deviation | 1.76 | |||
| Variance | 3.11 | |||
| Information Ratio | 0.0809 | |||
| Jensen Alpha | 0.1543 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0994 | |||
| Treynor Ratio | 0.2598 | |||
| Maximum Drawdown | 11.6 | |||
| Value At Risk | (1.98) | |||
| Potential Upside | 3.1 | |||
| Downside Variance | 2.06 | |||
| Semi Variance | 1.38 | |||
| Expected Short fall | (1.46) | |||
| Skewness | 1.09 | |||
| Kurtosis | 3.72 |
Consider Teva Pharma's intraday indicators
Teva Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Teva Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Teva Pharma Corporate Filings
8K | 18th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 16th of April 2024 Other Reports | ViewVerify | |
13A | 9th of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 7th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Teva Stock media impact
Far too much social signal, news, headlines, and media speculation about Teva Pharma that are available to investors today. That information is available publicly through Teva media outlets and privately through word of mouth or via Teva internal channels. However, regardless of the origin, that massive amount of Teva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Teva Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Teva Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Teva Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Teva Pharma alpha.
Teva Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Teva Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Teva Pharma Industries Historical Investor Sentiment
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Teva Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Teva Pharma.
Teva Pharma Maximum Pain Price across 2024-05-03 Option Contracts
Teva Pharma's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Teva Pharma close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Teva Pharma's options.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Teva Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Teva Pharma Corporate Directors
Teva Pharma corporate directors refer to members of a Teva Pharma board of directors. The board of directors generally takes responsibility for the Teva Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Teva Pharma's board members must vote for the resolution. The Teva Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Moshe Many | Independent Director | Profile | |
| Richard Lerner | Independent Director | Profile | |
| Galia Maor | Independent Director | Profile | |
| JeanMichel Halfon | Statutory - independent director | Profile |
How to buy Teva Stock?
To provide specific investment advice or recommendations on Teva Pharma Industries stock, we recommend investors consider the following general factors when evaluating Teva Pharma Industries. This will help you to make an informed decision on whether to include Teva Pharma in one of your diversified portfolios:- Examine Teva Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Teva Pharma's leadership team and their track record. Good management can help Teva Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Teva Pharma's business and its evolving consumer preferences.
- Compare Teva Pharma's performance and market position to its competitors. Analyze how Teva Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Teva Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Teva Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Teva Pharma Industries stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Teva Pharma Industries is a good investment.
Already Invested in Teva Pharma Industries?
The danger of trading Teva Pharma Industries is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Teva Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Teva Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Teva Pharma Industries is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Teva Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.